Skip to main content

Moberg Pharma Annual Report 2018

Moberg Pharma´s Annual Report for 2018 has been published and is available on

About this information
This is information that Moberg Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the contact persons set out below at 08.30 CET on April 16, 2019.

For additional information, please contact:
Peter Wolpert, CEO, phone: +46 707 35 7135, e-mail:

Anna Ljung, CFO, phone: +46 707 66 6030, e-mail:

About Moberg Pharma,
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, for which phase 3 data in 800+ patients is expected in late 2019 in North America and the first half of 2020 in Europe. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).